COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients

Trial Profile

COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs Coversin (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COBALT
  • Sponsors Akari Therapeutics
  • Most Recent Events

    • 06 Feb 2018 According to an Akari Therapeutics media release, the final three patients enrolled in COBALT clinical trial with PNH who have never received a complement blocking therapy and now have completed the trial.
    • 06 Feb 2018 Status changed from recruiting to completed, according to an Akari Therapeutics media release.
    • 08 Dec 2017 Results published in the Akari Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top